FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110557599> ?p ?o ?g. }

• W2110557599 endingPage "305" @default.
• W2110557599 startingPage "297" @default.
• W2110557599 abstract "Patients with type 2 diabetes mellitus have a higher rate of restenosis following angioplasty. Peroxisome proliferator activator receptor-alpha (PPAR) and gamma ligands such as fenofibrate and rosiglitazone, respectively, have been shown to have protective effects on the vessel wall. We studied the effect of fenofibrate and rosiglitazone on intimal hyperplasia in the Zucker rat, a model for insulin resistance and type 2 diabetes mellitus, following balloon catheter-induced injury.Three groups of 13-week-old female fatty Zucker rats were administered an aqueous suspension of either 3 mg/kg/d rosiglitazone (n=7) or 150 mg/kg/d fenofibrate (n=6) by gavage, or served as controls (n=9). In addition, two groups of 13-week-old female lean Zucker rats were either administered 3 mg/kg/d rosiglitazone (n=6) or served as controls (n=6). Carotid balloon injury was induced 1 week after the drugs were started. The drug administration was continued for 3 weeks. A 2-mm balloon catheter was introduced through the femoral artery to the left carotid. The balloon was inflated to 4 atmospheres for 20 seconds and then was deflated to 2 atmospheres and dragged down to the aorta. The rats were killed 3 weeks after the injury. The carotid intima/media ratio was calculated. Intimal hyperplasia after carotid balloon-induced injury in the fatty Zucker rats was significantly reduced in the group treated with rosiglitazone (0.18 +/- 0.29) compared with the untreated group (0.97 +/- 0.13; P<.01). Plasma glucose, triglyceride, and insulin levels were elevated, indicative of the presence of insulin resistance; rosiglitazone treatment significantly reduced insulin and triglyceride levels without decreasing glucose. Rosiglitazone treatment also reduced, but to a lesser extent, the intimal hyperplasia in the lean Zucker rats (0.57 +/- 0.10 vs 1.06 +/- 0.12 treated and untreated, respectively; P<.01); however, it had no effect on insulin, triglyceride, or glucose levels in this group. The intimal hyperplasia in the fatty Zucker rats treated with fenofibrate was not reduced compared with controls (0.84 +/- 0.26 vs 0.97 +/- 0.13, respectively); fenofibrate reduced insulin and triglyceride, but not glucose levels, in these animals.The PPAR-gamma ligand rosiglitazone, but not the PPAR-alpha ligand fenofibrate, decreases intimal hyperplasia following balloon injury in both fatty and lean Zucker rats. This effect of the PPAR-gamma ligand was independent of glycemia, insulin, and lipid levels, and was more pronounced in insulin-resistant rats." @default.
• W2110557599 created "2016-06-24" @default.
• W2110557599 creator A5006211510 @default.
• W2110557599 creator A5017747404 @default.
• W2110557599 creator A5034671525 @default.
• W2110557599 creator A5037734190 @default.
• W2110557599 creator A5060968419 @default.
• W2110557599 creator A5072181824 @default.
• W2110557599 creator A5077027153 @default.
• W2110557599 date "2003-12-01" @default.
• W2110557599 modified "2023-09-27" @default.
• W2110557599 title "Differential Effects of Peroxisome Proliferator Activator Receptor-α and γ Ligands on Intimal Hyperplasia After Balloon Catheter-Induced Vascular Injury in Zucker Rats" @default.
• W2110557599 cites W1210910152 @default.
• W2110557599 cites W1968873332 @default.
• W2110557599 cites W1969756099 @default.
• W2110557599 cites W1970106273 @default.
• W2110557599 cites W1985075979 @default.
• W2110557599 cites W1985401361 @default.
• W2110557599 cites W1989619519 @default.
• W2110557599 cites W1992280526 @default.
• W2110557599 cites W2008048680 @default.
• W2110557599 cites W2009381728 @default.
• W2110557599 cites W2012978778 @default.
• W2110557599 cites W2014663082 @default.
• W2110557599 cites W2014877159 @default.
• W2110557599 cites W2035182977 @default.
• W2110557599 cites W2043235601 @default.
• W2110557599 cites W2043566560 @default.
• W2110557599 cites W2044463761 @default.
• W2110557599 cites W2050904588 @default.
• W2110557599 cites W2061807515 @default.
• W2110557599 cites W2069090643 @default.
• W2110557599 cites W2082049752 @default.
• W2110557599 cites W2082477354 @default.
• W2110557599 cites W2088672562 @default.
• W2110557599 cites W2090635919 @default.
• W2110557599 cites W2095647681 @default.
• W2110557599 cites W2102133507 @default.
• W2110557599 cites W2103375075 @default.
• W2110557599 cites W2113225891 @default.
• W2110557599 cites W2114383361 @default.
• W2110557599 cites W2128300830 @default.
• W2110557599 cites W2131867773 @default.
• W2110557599 cites W2132597103 @default.
• W2110557599 cites W2159602871 @default.
• W2110557599 cites W2161099952 @default.
• W2110557599 cites W2164367541 @default.
• W2110557599 cites W2166395631 @default.
• W2110557599 cites W2168332555 @default.
• W2110557599 cites W2168978324 @default.
• W2110557599 cites W2169830874 @default.
• W2110557599 cites W2320364919 @default.
• W2110557599 cites W56664697 @default.
• W2110557599 doi "https://doi.org/10.1177/107424840300800407" @default.
• W2110557599 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14740079" @default.
• W2110557599 hasPublicationYear "2003" @default.
• W2110557599 type Work @default.
• W2110557599 sameAs 2110557599 @default.
• W2110557599 citedByCount "38" @default.
• W2110557599 countsByYear W21105575992012 @default.
• W2110557599 countsByYear W21105575992016 @default.
• W2110557599 countsByYear W21105575992018 @default.
• W2110557599 crossrefType "journal-article" @default.
• W2110557599 hasAuthorship W2110557599A5006211510 @default.
• W2110557599 hasAuthorship W2110557599A5017747404 @default.
• W2110557599 hasAuthorship W2110557599A5034671525 @default.
• W2110557599 hasAuthorship W2110557599A5037734190 @default.
• W2110557599 hasAuthorship W2110557599A5060968419 @default.
• W2110557599 hasAuthorship W2110557599A5072181824 @default.
• W2110557599 hasAuthorship W2110557599A5077027153 @default.
• W2110557599 hasConcept C126322002 @default.
• W2110557599 hasConcept C134018914 @default.
• W2110557599 hasConcept C139059822 @default.
• W2110557599 hasConcept C2778110834 @default.
• W2110557599 hasConcept C2778283817 @default.
• W2110557599 hasConcept C2778583881 @default.
• W2110557599 hasConcept C2779305218 @default.
• W2110557599 hasConcept C2779306644 @default.
• W2110557599 hasConcept C2779751240 @default.
• W2110557599 hasConcept C2780152017 @default.
• W2110557599 hasConcept C2910068830 @default.
• W2110557599 hasConcept C2987047532 @default.
• W2110557599 hasConcept C2992686903 @default.
• W2110557599 hasConcept C2993470428 @default.
• W2110557599 hasConcept C555293320 @default.
• W2110557599 hasConcept C71924100 @default.
• W2110557599 hasConceptScore W2110557599C126322002 @default.
• W2110557599 hasConceptScore W2110557599C134018914 @default.
• W2110557599 hasConceptScore W2110557599C139059822 @default.
• W2110557599 hasConceptScore W2110557599C2778110834 @default.
• W2110557599 hasConceptScore W2110557599C2778283817 @default.
• W2110557599 hasConceptScore W2110557599C2778583881 @default.
• W2110557599 hasConceptScore W2110557599C2779305218 @default.
• W2110557599 hasConceptScore W2110557599C2779306644 @default.
• W2110557599 hasConceptScore W2110557599C2779751240 @default.
• W2110557599 hasConceptScore W2110557599C2780152017 @default.
• W2110557599 hasConceptScore W2110557599C2910068830 @default.
• W2110557599 hasConceptScore W2110557599C2987047532 @default.

• next